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(Mg2+) homeostasis have implications for cell physiology. The
cyclin M family, CNNM, perform key functions in the transport of
Mg2+ across cell membranes. Herein, we aimed to elucidate the
role of CNNM4 in the development of non-alcoholic steatohe-
patitis (NASH).
Methods: Serum Mg2+ levels and hepatic CNNM4 expression
were characterised in clinical samples. Primary hepatocytes were
cultured under methionine and choline deprivation. A 0.1%
methionine and choline-deficient diet, or a choline-deficient
high-fat diet were used to induce NASH in our in vivo rodent
models. Cnnm4 was silenced using siRNA, in vitro with Dhar-
maFECT and in vivo with Invivofectamine® or conjugated to N-
acetylgalactosamine.
Results: Patients with NASH showed hepatic CNNM4 over-
expression and dysregulated Mg2+ levels in the serum. Cnnm4
silencing ameliorated hepatic lipid accumulation, inflammationwords: Non-alcoholic steatohepatitis; NASH; Cyclin M4; CNNM4; Magnesium;
rapy; siRNA; Endoplasmic reticulum stress; Microsomal triglyceride transfer
tein; MTP.
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Journal of Hepatologyknockdown in hepatocytes induced cellular Mg2+ accumulation,
reduced endoplasmic reticulum stress, and increased micro-
somal triglyceride transfer activity, which promoted hepatic lipid
clearance by increasing the secretion of VLDLs.
Conclusions: CNNM4 is overexpressed in patients with NASH
and is responsible for dysregulated Mg2+ transport. Hepatic
CNNM4 is a promising therapeutic target for the treatment of
NASH.
Lay summary: Cyclin M4 (CNNM4) is overexpressed in non-
alcoholic steatohepatitis (NASH) and promotes the export of
magnesium from the liver. The liver-specific silencing of Cnnm4
ameliorates NASH by reducing endoplasmic reticulum stress and
promoting the activity of microsomal triglyceride transfer protein.
© 2021 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Dietary imbalances, such as a low intake of magnesium, are
recognised as the root cause of diseases. Although daily mag-
nesium recommended intake is 300–400 mg/day, there is a
growing concern about decreased intake in last decade, attrib-
utable to changes in dietary habits and food processing.1,2 Its
ionic form, Mg2+, is the most abundant divalent cation in the cell
and it is required as a cofactor for over 300 enzymatic reactions.32021 vol. 75 j 34–45
An intricate network of Mg2+ transporters participate in its up-
take and excretion, allowing its flux across cellular membranes,
thus impacting Mg2+ homeostasis and distribution.1
Mg2+ supplementation reduces mortality from hepatic com-
plications arising from alcohol intake or steatosis.4 Hypo-
magnesaemia is present in several comorbidities of non-
alcoholic fatty liver disease (NAFLD) such as insulin resistance
and type 2 diabetes,5 cardiovascular complications,6 and
obesity.7 Moreover, deficiencies in Mg2+ are related to inflam-
matory responses, mitochondrial dysfunction, and decreased
activity of the antioxidant system, all features of liver diseases.8
The term NAFLD encompasses a group of pathologies char-
acterised by chronicity with serial progression from steatosis to
non-alcoholic steatohepatitis (NASH) and cirrhosis.9 Such pro-
gression is mediated by the increased production of reactive
oxygen species (ROS), lipotoxicity, mitochondrial dysfunction,
and the development of endoplasmic reticulum (ER) stress.10
Remarkably, ER stress has been proposed to be an important
mechanism because it disrupts calcium (Ca2+) transport through
ATPases11 and leads to protein misfolding.12 It has been widely
characterised in both NAFLD and NASH patients, together with
impaired VLDL assembly and secretion.13,14
NAFLD is a global health problem with an estimated preva-
lence of around 25% among the adult population, being expected
to increase.9 Changes in lifestyle habits are the most common
recommendations for the clinical management of NAFLD, but it is
difficult to achieve the long-term compliance of patients, making
pharmacological alternatives attractive.
Among the various magnesiotropic proteins, the cyclin M
(CNNM) family and their Bateman-module-mediated interactions
with phosphatases of regenerating liver (PRLs) are of particular
interest.15 PRLs are implicated in tumour progression and metas-
tasis,16,17 including liver cancer, with Mg2+ perturbations reported
in such.18 Although the CNNMs emerged as interacting molecular
partners of PRLs,17 a new perspective proposes targeting CNNMs to
modulate Mg2+ homeostasis more specifically.19 The functions of
hepatic CNNMs in this regard are unknown, and their significance
as pharmacological targets remains underexplored.
In the present study, we demonstrated the relevance of the
differential expression of CNNM4 in NASH development, showing
its functional role in transporting hepatic Mg2+. Moreover, we
identified CNNM4 as a potential target for NASH treatment.
Patients and methods
Patients
Measurements of serum Mg2+ and hepatic CNNM1-4 mRNA, and
immunohistochemical CNNM4 analysis were performed in
different cohorts recruited at the Hospital Marqués de Valdecilla,
Santander, Spain (Fig. S1A and B).
Animal maintenance and preclinical studies
Mice were maintained with ad libitum access to water and a
choline-deficient diet with 0.1% methionine (0.1% MCDD) or a
choline-deficient, high-fat diet (CD-HFD). A control group was
maintained on a regular diet (SC diet).
Treatment of primary mouse hepatocytes and THLE-2 cells
Upon attachment, isolated mouse primary hepatocytes were
transfected by overnight incubation with siRNA using Dharma-
FECT 1 or a CNNM4 expression plasmid using jetPRIME®. CellsJournal of Hepatologywere maintained and incubated for an additional 24 h under
different conditions.
Cnnm4 silencing in vivo
Mice fed a 0.1% MCDD for 2 weeks or a CD-HFD for 3 weeks were
repeatedly administered an siRNA using Invivofectamine® 3.0
Reagent through tail vein injection. Mice were sacrificed after 4
weeks on 0.1% MCDD and 6 weeks on CD-HFD, respectively. For
Cnnm4 GalNAc-siRNA delivery, mice fed for 3 weeks on 0.1%
MCDD were treated once, subcutaneously, and sacrificed after a
total of 6 weeks on the diet. Samples of liver, white adipose
tissue (WAT), and serum were collected.
Statistical analysis
All the experimentswere performed at least in triplicate, with n = 3
(in vitro) and n = 4 (in vivo). The data are expressed as mean ± SEM
and represent the fold change vs. control mean value when indi-
cated. Statistical significance was determined using Prism 8
(GraphPad Software, San Diego, CA, USA). Groups were compared
by 1-way analysis of variance (ANOVA) followed by post hoc Bon-
ferroni tests (for 3 or more groups) or the Student t test (for 2
groups).
Results
CNNM4 is overexpressed in clinical and preclinical NASH
To investigate Mg2+ dysregulation in NASH, we determined Mg2+
levels in sera from a cohort of 50 age- and BMI-matched patients
(Fig. S1A), observing increased levels of the cation in NASH pa-
tients (Fig. 1A). Mg2+ levels did not correlate with other NASH
biomarkers (data not shown).
Considering the magnesiotropic role of the CNNM family,19 we
sought to assess whether dysregulated CNNM expression could be
the cause of the elevated serumMg2+. The hepatic mRNA levels of
each CNNM were assessed in another cohort of 40 patients (Fig.
S1B), showing a significant overexpression of CNNM1 and CNNM4
in NASH patients (Fig.1B). In addition, an increase in Cnnm4mRNA
expression was observed in primary hepatocytes treated with
methionine and choline-deficient (MCD) medium (Fig. 1C), an in
vitro model that displays features of NASH such as ROS over-
production and lipid accumulation.20,21
Similarly, hepatic CNNM4 overexpression in NASH was
confirmed by immunohistochemical protein determination in
clinical samples (Fig. 1D) and animal models – mice fed a 0.1%
MCDD (Fig. 1E) and CD-HFD (Fig. 1F). These animal models also
showed elevated Cnnm4 mRNA, as did primary hepatocytes (Fig.
S1C and D). By contrast, Cnnm1 overexpression was observed in
neither the in vitro nor in vivo NASH models. To evaluate protein
stability, human THLE-2 cells were treated with MLN4924 to
inhibit NEDDylation, which prevents proteasome-mediated
degradation,22 resulting in decreased CNNM4 expression (Fig.
S1E). The expression of other Mg2+ transporters was deter-
mined in animal models (Fig. S1F) and clinical samples (Fig. S1G),
showing that CNNM4 is unique among Mg2+ transporters in its
upregulation in all conditions.
Targeting CNMM4 ameliorates NASH
The possible role of CNNM4 in NASH development was exam-
ined by in vitro screening by specifically silencing each Cnnm in
primary hepatocytes using small interfering RNA (siRNA). Tar-
geting Cnnm4 (siCnnm4) alone effectively reduced MCD-induced
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Fig. 1. CNNM4 is overexpressed in NASH patients and preclinical animal models. (A) Magnesium determination in serum and (B) hepatic levels of CNNM1-4
mRNA in different cohorts of healthy individuals, patients with steatosis and patients with NASH. (C) Levels of Cnnm1-4 mRNA in primary hepatocytes stimulated
with MCD medium. (D) Liver immunohistochemical staining and quantification for CNNM4 in a cohort of healthy individuals, patients with steatosis and patients
with NASH, as well as mice fed (E) a 0.1% MCDD or (F) a CD-HFD. Scale bar corresponds to 100 lm. *p <0.05, ***p <0.001, and ****p <0.0001 vs. healthy/ctrl/SC diet.



















































































































































































Ctrl MCD + siCtrl
MCD + siCnnm2 MCD + siCnnm3
MCD + siCnnm1
MCD + siCnnm4
Fig. 2. Targeting CNNM4 reduces lipid accumulation in in vitro and in vivo NASH models. (A) BODIPY staining micrographs and quantification in primary
hepatocytes transfected with siRNA against Cnnm1-4 (siCnnm1-4) and stimulated with MCD for 24 h. Micrographs of CNNM4 and Sudan Red staining and
respective quantification in mice fed (B) a 0.1% MCD diet (0.1% MCDD) or (C) a CD-HFD, and treated with Cnnm4 siRNA (siCnnm4) or an unrelated control (siCtrl).
Scale bar corresponds to 50 lm. *p <0.05, **p <0.01, and ***p <0.001 vs. Ctrl/SC diet; #p <0.05, ##p <0.01, and ###p <0.001 vs. MCD + siCtrl/0.1% MCDD + siCtrl/CD-
HFD + siCtrl. CD-HFD, choline-deficient high-fat diet; MCD, methionine and choline-deficient; MCDD, MCD diet; NASH, non-alcoholic steatosis; SC diet, regular
diet; siRNA, small interfering RNA.
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mRNA was evaluated, confirming the specific and effective
silencing of Cnnm (Fig. S2A) and eliminating the possibility of Prl
regulation when targeting Cnnm4 (Fig. S2B). Additionally,
CNNM4 silencing in THLE-2 cells also reduced MCD-induced lipid
accumulation (Fig. S2C and D).
Taking into consideration the CNNM4 overexpression
observed in NASH, and the siCnnm4-derived reduction of lipid
accumulation, the therapeutic potential of silencing Cnnm4 in
vivo was explored. Mice were fed a 0.1% MCDD to induce stea-
tosis development, increased oxidative stress, inflammation, and
fibrosis in a short period of time.23 At 2 weeks, by which stea-
tosis21 and CNNM4 overexpression are observable (Fig. 1E), 0.1%
MCDD-fed mice were separated into 2 groups and treated
repeatedly with either an siRNA against Cnnm4 (0.1% MCDD +
siCnnm4) or an unrelated control (0.1% MCDD + siCtrl), using
Invivofectamine 3.0®. The mice were sacrificed at the fourth
week. Interestingly, the mice fed the 0.1% MCDD showed hepatic
CNNM4 overexpression, whereas Cnnm4 silencing reduced diet-































































































































































































Fig. 3. Magnesium distribution after specific silencing of Cnnm4. (A) Magne
silencing (siCnnm4) compared with non-treated (siCtrl) mice. (B) Biochemical stru
intracellular magnesium levels and (D) extracellular magnesium levels in prima
responds to 100 lm. (E) Intracellular magnesium and (F) extracellular magnesiu
resentation of CNNM4-dependent magnesium fluctuations in liver and in circulat
+ siCtrl/siCtrl. CD-HFD, choline-deficient high-fat diet; CNNM4, cyclin M4; MagS
MCDD, methionine and choline deficient diet; SC diet, regular diet; siRNA, small
Journal of Hepatologyactin (aSMA) staining revealed that fibrosis, another NASH
hallmark, was induced by 0.1% MCDD and attenuated by siCnnm4
(Fig. S2F). Furthermore, the treatment also reduced serum
alanine aminotransferase (ALT) levels, a marker of liver damage
(Fig. S2G).
In a different NASH murine model, mice were fed a CD-HFD,
as this leads to a pattern of pathology more similar to that
observed in humans.24 Although studies using this model tend to
be performed for longer than 6 weeks,24 our group previously
showed that mice developed early NASH phenotypes comprising
weight gain, steatosis, and inflammation as early as this point in
time.21 After 3 weeks on the diet, at which point CNNM4 was
already overexpressed (Fig. 1F), the CD-HFD-fed group was
divided and treated with siCnnm4 (CD-HFD + siCnnm4) or siCtrl
(CD-HFD + siCtrl). They were sacrificed after 6 weeks and,
similarly to in the previous results, the mice fed the CD-HFD
showed hepatic CNNM4 overexpression, while the siRNA ther-
apy reduced steatosis (Fig. 2C and Fig. S2H) and fibrosis devel-

































































































































sium in serum from mice fed a 0.1% MCDD or CD-HFD with specific Cnnm4
cture of non-targeted MagS and MagS-TPP probes. (C) Micrographs and relative
ry hepatocytes treated with an siRNA against Cnnm4 (siCnnm4). Scale bar cor-
m levels in primary hepatocytes treated with siCnnm1-3. (G) Schematic rep-
ion **p <0.01 vs. SC diet; #p <0.05, and ##p <0.01 vs. 0.1% MCDD + siCtrl/CD-HFD
, magnesium-specific; MagS-TPP, mitochondrion-targeted magnesium-specific;
-interfering RNA.
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Research Article NAFLD and Alcohol-Related Liver DiseasesCNNM4 acts in the liver as a magnesium exporter
Despite the magnesiotropic role of CNNM4 in kidney epithelia,25
its physiological function in the liver remains largely unknown.
The possible relationship between increased serum Mg2+ levels
and hepatic CNNM4 overexpression (Fig. 1A and D) led us to
anticipate a modulation of the cation in the studied NASH animal
models. The measurement of Mg2+ in the serum revealed an
increase in CD-HFD-fed mice and a decrease under siCnnm4
treatment in both the CD-HFD and 0.1% MCDD models (Fig. 3A).
To confirm the hypothesis of CNNM4 being a hepatic Mg2+
exporter, CNNM4-related Mg2+ flux in hepatocytes was assessed
in vitro. Fluorescent staining with the ratiometric probe MagS
was used to estimate the relative levels of cytosolic free Mg2+ in
live cells treated with siCnnm4. MagS is an analogue of Mag-
FURA-2, developed by the Buccela group,26 which displays
similar metal recognition but enhanced optical properties.
Furthermore, taking into consideration the key role of mito-
chondria in hepatocyte function,27,28 we sought to explore the
mitochondrial Mg2+ levels in the aforementioned siCnnm4 con-
ditions. For this purpose, we developed MagS-TPP, a targeted
variant functionalised with a phosphonium group for delivery to
the mitochondrial matrix (Fig. 3B). The new dye exhibits a
selectivity profile similar to MagS and binds to Mg2+ with an
apparent dissociation constant suitable for the detection of
typical intracellular concentrations of free Mg2+ (Fig. S3).
Mitochondrion- and non-targeted fluorescent indicators were
applied, revealing an increase in both cytosolic and mitochon-
drial free Mg2+ levels in cells with reduced Cnnm4 expression



























































































































Fig. 4. Modulation of intracellular lipid content by CNNM4. (A) Relative intrac
hepatocytes under MCD stimulation and treated with a Cnnm4 siRNA (siCnnm4
maintained for 24 h under magnesium depletion (0 mM Mg2+) and transfected wi
mRNA levels in primary hepatocytes transfected for 6 h with an empty or CNN
isolated mouse hepatocytes transfected for 6 h with an empty/CNNM4 expressio
group (1 mM Mg2+). Scale bar corresponds to 100 lm. *p <0.05, **p <0.01, ***p <0.0
+ siCtrl/0 mM Mg2+ + siCtrl. CD-HFD, choline-deficient high-fat diet; CNNM4, cy
nesium-specific; MCD, methionine and choline deficient; siRNA, small interferin
38 Journal of Hepatologyextracellular medium (Fig 3D). The silencing of other Cnnm
family members did not lead to significant alterations in intra- or
extracellular Mg2+ (Fig. 3E and F), thus eliminating their possible
contribution to Mg2+ homeostasis in the hepatocyte. These re-
sults support the notion that the observed decrease in serum
Mg2+ of mice treated with siCnnm4 could be a consequence of its
accumulation in the liver (Fig. 3G).
CNNM4-mediated magnesium accumulation reduces lipid
content
The association between CNNM4 and magnesium efflux
prompted us to characterise the contribution of Mg2+ homeo-
stasis to NASH development. The relative content of the cation in
primary hepatocytes under MCD conditions was determined,
showing an MCD-induced decrease in Mg2+ and an increase
upon silencing Cnnm4 (Fig. 4A). Taking the latter into consider-
ation, a possible inverse relationship between hepatic Mg2+ and
lipid content was investigated. Magnesium depletion in the cell
medium (0 mM Mg2+) resulted in an increased hepatocyte lipid
content, while silencing Cnnm4 reduced this effect (Fig. 4B). In
line with the results of a clinical trial addressing the beneficial
properties of magnesium,4 Mg2+ supplementation (5 mM Mg2+)
reverted MCD-induced lipid accumulation in hepatocytes
without effects under normal conditions (1 mM Mg2+) (Fig. S4A).
Neither Mg2+ depletion nor supplementation affected Cnnm4
expression (data not shown).
To eliminate the possibility of other Mg2+ transporters
contributing to siCnnm4-induced lipid reduction, their expres-



































































































































































ellular magnesium determination by MagS and MagS-TPP staining in primary
). (B) BODIPY staining micrographs and quantification in murine hepatocytes
th siCnnm4. (C) Relative intracellular magnesium determination and (D) Cnnm4
M4 vector. (E) BODIPY staining micrographs and respective quantification in
n vector and stimulated for 24 h with magnesium (5 mM Mg2+) vs. a control
01, and ****p <0.0001 vs. Ctrl/Empty vector; ##p <0.01 and ###p <0.001 vs. MCD
clin M4; MagS, magnesium-specific; MagS-TPP, mitochondrion-targeted mag-
g RNA.
2021 vol. 75 j 34–45
increase in the expression of Transient Receptor Protein Melastatin
6 (Trpm6) (Fig. S4B), suggesting that the lipid reduction may also
be the result of increased Mg2+ entry. As there is no commercial
inhibitor for TRPM6, its isoform 7 was inhibited with 2-
aminoethyl diphenyl borinate (2-APB)29 to further investigate
the contribution of Mg2+ entry. We observed that the lipid
accumulation induced by inhibiting Mg2+ import was normalised
by siCnnm4 (Fig. S4C). Finally, the functional relationship be-
tween cellular Mg2+ levels and steatosis was investigated by
overexpressing CNNM4 via transient transfection, which reduced
Mg2+ levels (Fig. 4C and D) and raised lipid contents in hepato-
cytes (Fig. 4E). Remarkably, Mg2+ supplementation did not
attenuate CNNM4-induced lipid accumulation (Fig. 4D and E).
Endoplasmic reticulum and oxidative stress are reduced by
silencing cyclin M4
Considering that ROS production and inflammation are major
drivers of NASH progression,10,28 mitochondrial ROS were


























































































































































































Fig. 5. Specific Cnnm4 silencing reduces oxidative and ER stress in in vitro and
levels, (C) Ca2+ release capacity of ER over time and (D) micrographs of ER-tracke
MCD medium and transfected with a Cnnm4 (siCnnm4) or control (siCtrl) siRNA
patocytes treated for 24 h with tunicamycin, MCD, or Ctrl medium and treated wit
lm) and DHE staining for liver from mice fed a 0.1% MCDD and treated with siCnn
GRP78), x-box binding protein 1 isoform s (XBP1s), phosphoSer51-eukaryotic init
phosphoThr202/Thyr204-ERK1/2, and phosphoSer235/236-S6 ribosomal protein (S6). M
or CD-HFD treated with siCnnm4 or siCtrl. *p <0.05, **p <0.01, ***p <0.001, and ****
MCD + siCtrl/0.1% MCDD + siCtrl/MCD + vehicle + siCtrl/CDHFD + siCtrl; pp <0.05
diet; CNNM4, cyclin M4; DHE, dihydroxyethyl; ER, endoplasmic reticulum; MC
steatohepatitis; ROS, reactive oxygen species; SC, regular diet; siRNA, small inter
Journal of Hepatologyinduced ROS production upon silencing Cnnm4 (Fig. 5A). The
development of ER stress is also considered a ‘second hit’, linked
to oxidative stress30 and with an existing Mg2+ flux between the
ER and mitochondria.31 Thus, we hypothesised that ER integrity
might be affected by CNNM4-induced Mg2+ fluctuations in NASH.
Therefore, cytosolic calcium (Ca2+), an ER-stress indicator, was
quantified in primary hepatocytes. The increased [Ca2+]cytosol
observed under MCD stimulation and siRNA-derived attenuation
(Fig. 5B), together with the partial co-localisation of Mg2+ and ER
(Fig. S5A), suggested a protective effect of silencing Cnnm4, not
only for mitochondria, but also for the ER. This was further
addressed by characterising the release of Ca2+ from the ER by
stimulating primary hepatocytes with ATP, reported to promote
the P2Y receptor-mediated release of Ca2+ into the cytosol.32
Interestingly, an MCD-induced decreased capacity and then
normalisation upon silencing Cnnm4 were observed (Fig. 5C),
while ER labelling was decreased under the MCD and recovered
by Cnnm4 siRNA (Fig. 5D). The relationship between ER stress























































































Ctrl MCD + siCnnm4MCD + siCtrl
in vivo NASH models. (A) Relative mitochondrial ROS levels, (B) cytosolic Ca2+
r red staining and quantification in primary hepatocytes cultured for 24 h in a
. Scale bar corresponds to 100 lm. (E) BODIPY determination in primary he-
h siCnnm4 or siCtrl. (F) Representative micrographs (scale bar corresponds to 50
m4 or siCtrl. (G) Western blot analysis of binding immunoglobulin protein (BIP/
iation factor 2a (eIF2a), phosphoThr172-AMP dependent protein kinase (AMPK),
ouse livers from different groups were compared: healthy (SC diet), 0.1% MCDD,
p <0.0001 vs. Ctrl/Ctrl + vehicle/SC diet; #p <0.05, ##p <0.01, and ###p <0.001 vs.
and ppp <0.01 for vehicle vs. tunicamycin. CD-HFD, choline-deficient high-fat
D, methionine and choline deficient; MCDD, MCD diet; NASH, non-alcoholic
fering RNA.
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Research Article NAFLD and Alcohol-Related Liver Diseaseshepatocytes with tunicamycin, an ER-stress inducer.33 A dose-
dependent lipid accumulation was observed after 24 h of treat-
ment, while siCnnm4 led to a decrease in lipid content (Fig. 5E
and Fig. S5B).
When characterising ROS production in vivo, siCnnm4-treated
mice showed reduced dihydroxiethidium (DHE) staining (Fig.
5F), probably as a result of the oxidative activity measured by
various pathways (Fig. S5C–F). Although oxidative stress was not
determined in the study with CD-HFD mice, the observed
reduction in fatty acid oxidation (Fig. S5G) is consistent with a
ROS reduction. The regulation of the oxidative stress response
prompted us to evaluate ER stress in the in vivo models of NASH
using different markers,34 demonstrating upregulation in both
NASH models and reduction under siCnnm4, suggesting that the
latter diminished the ER-stress response (Fig. 5G and Fig. S5G).
ER-stress associated signalling pathways were also evaluated,




































































































































































Fig. 6. Inhibition of CNNM4 expression promotes lipid export by activating MT
a MCD medium and transfected with a Cnnm4 siRNA (siCnnm4) or unrelated contr
HFD and treated with siCnnm4 or siCtrl. (C) Relative apolipoprotein B100 (APOB
siCnnm4 or siCtrl. (D) Liver TG secretion rate in mice fed a 0.1% MCDD, treated wi
micrographs and quantification of primary hepatocytes cultured under MCD and
for 24 h or (F) an siRNA against Mtp (siMtp). Scale bar corresponds to 100 lm. *p <
###p <0.001, and ####p <0.0001 vs. 0.1% MCDD + siCtrl/CD-HFD + siCtrl/MCD +
lomitapide/siMtp. CD-HFD, choline-deficient high-fat diet; MCD, methionine an
protein; SC, regular diet; siRNA, small interfering RNA; TG, triacylglyceride.
40 Journal of HepatologyCNNM4 inhibition increases MTP activity, promoting VLDL
secretion
The formation of pre-VLDL, the first step of VLDL assembly, takes
place in the ER.36 During this step, a small number of tri-
glycerides (TGs) are associated with an apolipoprotein B (APOB)
molecule and embedded in a phospholipid monolayer by the
microsomal triglyceride transfer protein (MTP).36 The alterations
of ER integrity previously observed under MCD and the reversion
of such by siCnnm4 suggested a possible modulation of MTP
activity. Remarkably, the protein was increased upon silencing
Cnnm4 in both the primary hepatocytes (Fig. 6A) and in vivo
rodent NASH models (Fig. 6B).
The serum TGs of mice fed a 0.1% MCDD were found to
decrease, owing to intrahepatic lipid accumulation, and were
partially restored by Cnnm4 siRNA (Fig. S6A), suggesting an
improved VLDL secretion. Therefore, we determined the relative
APOB100 concentrations in the serum, an indicator of circulating































































































































































P activity. (A) Relative MTP activity in primary hepatocytes cultured for 24 h in
ol (siCtrl). (B) Relative MTP activity in livers frommice fed a 0.1% MCDD or a CD-
100) levels in sera from mice fed a 0.1% MCDD or CD-HFD and treated with
th siCnnm4 or siCtrl and after poloxamer P407 administration. BODIPY staining
treated with siCtrl or siCnnm4 and (E) a vehicle (DMSO) or 600 nM lomitapide
0.05 and ****p <0.0001 vs. SC diet/Ctrl + vehicle/Ctrl + siCtrl; #p <0.05, ##p <0.01,
vehicle + siCtrl/MCD + siCtrl; pp <0.05 and ppppp <0.0001 for vehicle/siCtrl vs.
d choline deficient; MCDD, MCD diet; MTP, microsomal triglyceride transfer
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conditions (Fig. 6C and Fig. S6B). The contribution of increased
lipid secretion mediated by VLDL was further confirmed by
measuring APOB100 in serum extracted directly from the cava
vein, with VLDLs as the main component, showing an increased
APOB100 content (Fig. S6C). The hepatic TG secretion rate, as
well as the VLDL content, were determined after administering
poloxamer P407 to inhibit lipoprotein lipase.37 Remarkably, both
the secretion rate and the VLDL lipid content tended to increase
upon silencing Cnnm4 (Fig. 6D and Fig. S6D). MTP was then
inhibited in primary hepatocytes by 24-h lomitapide incubation,
a selective inhibitor,38 or with a specific siRNA (siMtp). As ex-
pected, the lipid reduction observed upon CNNM4 knockdown
was absent under lomitapide stimulation (Fig. 6E) or Mtp
silencing conditions (Fig. 6F and Fig S6E).
The possible atherogenic secondary effects are a concern
when it comes to promoting VLDL secretion. Furthermore, when
determining the Mg2+ content in isolated VLDL, the observed
restoration in the group treated with the Cnnm4 siRNA (Fig. S7A)
suggested a possible impact on the WAT. The measurement of
the relative fatty acid oxidation (FAO) capacity of WAT revealed a
tendency to increase with the siRNA treatment (Fig. S7B),
together with an increased expression of genes involved in lipid
oxidation, mitochondrial biogenesis, and thermogenesis (Fig.
S7C). This result was corroborated in primary WAT adipocytes,
where Mg2+ supplementation increased glycerol production, an
indicator of lipolysis without subsequent non-esterified fatty
acid (NEFA) production (Fig. S7D). The same result was observed
with conditioned medium obtained from primary hepatocytes
cultured under MCD and siCnnm4 conditions (Fig. S7E).
The siRNA conjugation with GalNAc offers a potential therapy
Considerable progress has recently been made in the develop-
ment of oligonucleotide-based therapeutics, whereby the
silencing of target genes is being explored in clinical studies.39 To
transfer the presented discoveries into a therapeutic approach
suitable for clinical development, a newly identified Cnnm4
siRNA candidate was conjugated to an N-acetylgalactosamine
(GalNAc) cluster that binds to the asialo-glycoprotein receptors
predominantly expressed in hepatocytes. This technology offers
a potentially safe, specific, and efficient mode of delivery for
targeting therapeutic molecules to hepatocytes.40
The specific inhibition of Cnnm4 was achieved in primary
hepatocytes through receptor-mediated uptake by adding
different doses of a GalNAc-conjugated siRNA against Cnnm4
(GalNAc siRNA) directly to the culture medium (Fig. 7A). The lipid
accumulation induced by MCD medium was reduced by the
GalNAc siRNA treatment (Fig. 7B), and Mg2+ accumulation in
hepatocytes was observed indirectly through its decrease in the
extracellular medium (Fig. 7C). ROS overproduction upon MCD
stimulation was also reduced by treating the hepatocytes with
the conjugate (Fig. 7D).
Finally, the effectiveness of Cnnm4 GalNAc siRNA was evalu-
ated in vivo in mice fed a 0.1% MCDD for 6 weeks, leading to a
more severe NASH phenotype.21 The treatment was initiated at
the 3-week point with a single injection of different doses (1 or 5
mg/kg) of Cnnm4 GalNAc siRNA (0.1% MCDD + GalNAc siRNA) or
a control siRNA conjugate (0.1% MCDD + siCtrl). A specific and
significant inhibition of Cnnm4mRNA expressionwas detected in
mice administered either 1 or 5 mg/kg (Fig. 7E), while the Mg2+
levels in serum were reduced in line with a presumed hepatic
Mg2+ accumulation (Fig. 7F). Importantly, CNNM4 inhibition byJournal of HepatologyGalNAc siRNA significantly reduced hepatic lipid accumulation
and alleviated the inflammatory response and fibrosis develop-
ment (Fig. 7G).
Discussion
The studies described herein pinpoint CNNM4 as a key regulator
of Mg2+ homeostasis in hepatocytes and a potential therapeutic
target for NASH. To date, research performed on this cation in
liver pathologies has shown a protective effect of Mg2+ supple-
mentation4 and revealed Mg2+ deficiencies in patients with
cirrhosis or liver cancer.18 Indeed, hypomagnesaemia is
frequently observed in NASH comorbidities.6,7 However, there is
still a dearth of knowledge on the implications of Mg2+ pertur-
bations for the development of NASH, and nothing has been
reported about magnesiotropic proteins and their modulation in
the liver.
Previous studies have mainly focused on PRL, the interacting
partner of CNNM, associating its expression with poor prognosis
in multiple cancer types including liver,16,17 whereas studies of
CNNMs have been limited to their role in transporting Mg2+
across epithelia.25 Herein, we demonstrate that CNNM4 is a
contributor to NASH, as it is overexpressed in preclinical models
and clinical samples of the pathology. The reduction in CNNM4
expression in THLE-2 cells upon inhibiting NEDDylation suggests
the involvement of post-translational mechanisms in the mod-
ulation of the stability of CNNM4 during NASH. This is further
confirmed by the reduction of MCD-induced lipid accumulation
by the specific silencing of Cnnm4, which does not happen upon
silencing other Cnnms. Regarding the effect of targeting Cnnm4
on NASH development, preclinical studies in rodent models
showed promising effects of an siRNA-based therapy in mice fed
either a 0.1% MCDD or CD-HFD. Significantly, both diets increase
lipid accumulation and fibrosis development, but the siRNA
therapy ameliorates both hallmarks of the disease. The role that
CNNM4 may play in other cell populations such as hepatic
stellate cells requires more research, as do the possible post-
transcriptional and post-translational mechanisms that may
contribute to CNNM4 overexpression.
The role of the hepatocyte in NASH and its subsequent pro-
gression has been widely characterised.27,28 The silencing of
Cnnm4 may reduce oxidative activity, leading to reduced oxida-
tive stress, which could contribute to a reduction in fibrosis
development. Although the development of oxidative stress was
not characterised in the CD-HFD in vivo study, the observed
reduction in FAO and lipid contents prompts to expect a similar
reduction. The relevance of the hepatocyte in NASH progression
and the implications of modulating CNNM4 were further char-
acterised in mice fed a 0.1% MCDD for 6 weeks. Herein, we also
demonstrated that targeting CNNM4 ameliorated NASH, even
that with a more severe phenotype.21 To develop a possible
therapeutic approach, an siRNA was conjugated with GalNAc
allowing stable and liver-specific delivery,40 with results similar
to those observed when targeting Cnnm4 with the liposomal
siRNA formulation after 4 weeks on the 0.1% MCDD.
Although CNNM4 has been characterised as a Mg2+ trans-
porter in kidney epithelia,41 the CNNM4-mediated flux of the
cation in the liver remains unknown. Our research shows
CNNM4 to be a Mg2+ exporter in the hepatocyte, as its specific
silencing increases intracellular Mg2+. Hepatic siCnnm4-induced
Mg2+ accumulation was characterised in all the preclinical
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Fig. 7. Inhibition of CNNM4 expression by GalNAc)–siRNA conjugate reduces NASH in preclinical models Levels of (A) Cnnm1-3 mRNA and (C) magnesium in
extracellular medium from primary hepatocytes treated overnight with a GalNAc-conjugated siRNA against Cnnm4 (GalNAc siRNA) and a MCD medium. Relative
determination of (B) lipid accumulation and (D) mitochondrial ROS production in primary hepatocytes treated with an MCD and Ctrl or GalNAc siRNA. Relative
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currently the only feasible method because of the lack of avail-
able tools for directly measuring hepatic Mg2+ in vivo. CNNM4
overexpression in the clinical samples correlated with the
increased Mg2+ serum levels observed. The possible contribution
of other, non-liver-related factors was eliminated by the BMI and
age pairing of the samples. Similarly to clinical NASH, increased
serum levels of the cation were observed in mice fed a CD-HFD,
whereas in the 0.1% MCDD model, the lower Mg2+ content in the
diet may have masked the expected CNNM4-induced increase in
serum. The possible involvement of Mg2+ content in NASH-
inducing diets might be a topic of interest for future research.
The finding that hepatocyte Mg2+ content is inversely corre-
lated with lipid accumulation also suggests a possible role of the
cation in NASH. Decreases in intracellular Mg2+, whether induced
by MCD stimulation or transfection with the CNNM4 vector,
were accompanied by increased lipid accumulation. Accordingly,
Mg2+-depleted culture medium also increased hepatocyte lipid
content. Remarkably, the action of CNNM4 in modulating Mg2+
homeostasis prevails over that of other transporters, as the in-
hibition of Mg2+ import with 2-APB29 leads to an expected lipid
accumulation, which is reverted under siCnnm4 treatment. Mg2+
supplementation decreases hepatocyte lipid content under MCD
stimulation, whereas under vector-induced CNNM4 over-
expression, such supplementation is not sufficient to counteract
the increase. These observations suggest the relevance of not
only adequate Mg2+ intake, but also the correct balance of the
proteins implicated in its homeostasis, such as CNNM4.1,2
Combined with oxidative stress, ER stress has been charac-
terised as an additional driver of NASH progression,10,14 with a
demonstrated connection between these 2 ‘hits’.30 In our study,
the characterised MCD-induced development of ER stress was
reversed by silencing Cnnm4. Despite the current lack of effective
methods for determining the Mg2+ content in the ER, the partial
co-location observed and the recently characterised Mg2+ flux
between the ER and mitochondria31 suggest that the induced
Mg2+ accumulation somehow protects the hepatocyte from ER-
stress development. Likewise, the development of ER stress by
hepatocytes upon tunicamycin stimulation induces lipid accu-
mulation in a dose-dependent manner, and siCnnm4 reduced
this effect. In vivo, the ER stress response was shown to increase
under NASH development and be attenuated upon silencing
Cnnm4, a phenomenon involving the phosphorylation-mediated
activation of S6 and independent of other pathways such as
AMP-dependent protein kinase or extracellular signal-related
protein kinase 1/2.
The reduction of ER stress under Cnnm4 knockdown might be
the cause of the increased MTP activity observed. The MTP is
located in the ER and catalyses the first step of pre-VLDL for-
mation and transfer to the Golgi for its maturation,36 whereas
APOB100 is co-translationally expressed while MTP is func-
tioning.42 Thus, increased MTP activity is accompanied by
increased APOB100 in the serum. These findings, together with
the restoration of TGs in the serum of treated 0.1% MCDD-fed
mice and lipid content in secreted VLDLs, suggest that Cnnm4
knockdown may increase MTP activity in a direct or indirectlevels of (E) Cnnm1-4mRNA and (F) Mg2+ in serum, and (G) histological characteris
(aSMA and Sirius Red) in livers frommice fed a 0.1% MCDD and treated with siCtrl
##p <0.01, ###p <0.001, and ####p <0.01 vs. MCD + siCtrl/0.1% MCDD + siCtrl. CD-
GalNAc, N-acetylgalactosamine; MCD, methionine and choline deficient; MCDD,
siRNA, small interfering RNA.
Journal of Hepatologymanner and, consequently, promote VLDL secretion from the
liver. This is further supported by the observation that MTP in-
hibition in hepatocytes blocked the reduction of lipid accumu-
lation by Cnnm4 siRNA treatment. The possible implications of
other pathways involved in lipid resolution and the Mg2+-
induced changes in metabolic pathways require further
investigation.
Interestingly, secondary atherogenic effects from targeting
Cnnm4 are not expected as TGs are restored to normal levels
rather than above. Moreover, the hepatic Mg2+ accumulation
leads to the restoration of the cation in secreted VLDLs, which
may promote their catabolism by WAT, as the cation acts as a
cofactor in reactions involving ATP.3 Thus, Mg2+ restoration may
promote the lipolytic and FAO activities of WAT, as the increase
in glycerol production upon stimulating primary adipocytes with
Mg2+ or conditioned medium from primary hepatocytes is not
accompanied by increased NEFA production. Indeed, the
expression in the WAT of several genes involved in lipid catab-
olism increased in the group of mice treated with the Cnnm4
siRNA. Although the effect of CNNM4 on the oxidative activity of
WAT needs to be investigated more deeply, the present study
points out a possible anti-atherogenic effect of silencing Cnnm4.
In summary, CNNM4 appears to be a feasible candidate for
developing therapies against NASH. CNNM4-based therapy in-
duces hepatic Mg2+ and, consequently, reduces steatosis and
other hallmarks of the disease such as oxidative or ER stress,
while reducing fibrosis. Additionally, ER recovery might lead to
increased MTP activity, promoting VLDL formation, increasing
hepatic lipid export, and reducing lipid accumulation (see the
Graphical Abstract). Furthermore, the possibility of conjugating
the siRNA with a GalNAc molecule and the observed effective-
ness in ameliorating NASH, even that of a severe phenotype,
points to CNNM4 as an attractive hepatocyte target for
treatment.
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